Health and Fitness Health and Fitness
Tue, May 8, 2012
Mon, May 7, 2012
[ Mon, May 07th 2012 ] - Market Wire
00 A.M. Eastern Time
[ Mon, May 07th 2012 ] - Market Wire
2012 First Quarter Results

Uroplasty to Present at the 11th Annual JMP Securities Research Conference


Published on 2012-05-07 13:21:39 - Market Wire
  Print publication without navigation


Uroplasty to Present at the 11th Annual JMP Securities Research Conference -- MINNEAPOLIS, May 7, 2012 /PRNewswire/ --

Uroplasty to Present at the 11th Annual JMP Securities Research Conference

[ ]

MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 11thAnnual JMP Securities Research Conference at 12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in San Francisco.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at [ http://wsw.com/webcast/jmp17/upi/ ], or through Uroplasty's website at [ www.uroplasty.com ]. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].

cellpadding="0" cellspacing="0" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431

952.426.6140


SOURCE Uroplasty, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.uroplasty.com ]